These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8683454)

  • 1. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?
    Dutta S; Matsumoto Y; Ebling WF
    J Pharm Sci; 1996 Feb; 85(2):232-9. PubMed ID: 8683454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parameter estimability of biphasic response models.
    Dutta S; Ebling WF
    J Pharm Sci; 1997 Jan; 86(1):44-51. PubMed ID: 9002458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parameter estimation for sigmoid E
    Choe S; Lee D
    Transl Clin Pharmacol; 2017 Jun; 25(2):74-84. PubMed ID: 32133323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.
    Pai SM; Girgis S; Batra VK; Girgis IG
    AAPS J; 2009 Sep; 11(3):535-40. PubMed ID: 19629711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic parameter estimation: population size versus number of samples.
    Girgis S; Pai SM; Girgis IG; Batra VK
    AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of effect-controlled clinical trials of drugs with pharmacodynamic hysteresis using sparse data.
    Ebling WF; Matsumoto Y; Levy G
    Pharm Res; 1996 Dec; 13(12):1804-10. PubMed ID: 8987075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
    Keller F; Czock D; Zellner D; Giehl M
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Felodipine pharmacokinetics and plasma concentration vs effect relationships.
    Blychert E
    Blood Press Suppl; 1992; 2():1-30. PubMed ID: 1343111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacodynamic Modeling Using the Sigmoid E
    Proost JH; Eleveld DJ; Struys MMRF
    AAPS J; 2020 Dec; 23(1):10. PubMed ID: 33367961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A linearization approach for the model-based analysis of combined aggregate and individual patient data.
    Ravva P; Karlsson MO; French JL
    Stat Med; 2014 Apr; 33(9):1460-76. PubMed ID: 24488864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear enhancement of oxygen evolution in thylakoid membranes: modeling the effect of light intensity and beta-cyclodextrin concentration.
    Fragata M; Dudekula S
    J Phys Chem B; 2005 Aug; 109(30):14707-14. PubMed ID: 16852855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.